Litcius/Paper detail

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

Harini Natarajan, Andrew R. Crowley, Savannah E. Butler, Shiwei Xu, Joshua A. Weiner, Evan M. Bloch, Kirsten Littlefield, Wendy Wieland‐Alter, Ruth I. Connor, Peter F. Wright, Sarah E. Benner, Tania S. Bonny, Oliver Laeyendecker, David Sullivan, Shmuel Shoham, Thomas C. Quinn, H. Benjamin Larman, Arturo Casadevall, Andrew Pekosz, Andrew D. Redd, Aaron A.R. Tobian, Margaret E. Ackerman

2021mBio83 citationsDOIOpen Access PDF

Abstract

Convalescent plasma has been deployed globally as a treatment for COVID-19, but efficacy has been mixed. Better understanding of the antibody characteristics that may contribute to its antiviral effects is important for this intervention as well as offer insights into correlates of vaccine-mediated protection. Here, a survey of convalescent plasma activities, including antibody neutralization and diverse effector functions, was used to define plasma samples with broad activity profiles. These polyfunctional plasma samples could be reliably identified in multiple cohorts by multiplex assay, presenting a widely deployable screening test for plasma selection and investigation of vaccine-elicited responses.

Topics & Concepts

Convalescent plasmaVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Antibody2019-20 coronavirus outbreakSars virusMedicineImmunologyDiseaseInfectious disease (medical specialty)OutbreakPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing
Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma | Litcius